<ul>
<li>剩余的 540 万美元债务通过战略性股权转换为普通股偿还，没有附加的认股权证或调整条款</li>
<li>公司预计截至 12 月 31 日的资产负债表将不再反映任何未偿还的可转换债务</li>
<li>无债务的资产负债表为 2026 年的加速增长奠定了基础，预计将有潜在的药物批准和诊所扩展</li>
</ul>
<p>特拉华州威尔明顿，2025 年 12 月 18 日（GLOBE NEWSWIRE）-- NRx Pharmaceuticals, Inc.（纳斯达克：NRXP），一家临床阶段生物制药公司，今天宣布已通过普通股的股权转换向 Anson Funds, LLC 偿还了剩余的 540 万美元资产负债表债务。此交易没有附带认股权证或其他重新定价机制。Anson 最初向公司借款 1620 万美元，用于偿还之前的贷款和公司运营费用。通过此次偿还，公司预计在 2025 年日历年结束时将实现无债务的资产负债表。NRx 认为这一里程碑为公司的资本结构适当定位，以便在未来一年实现加速增长，预计将有药物批准和诊所扩展。</p>
<p>“我们感谢 Anson Funds 在生物技术股票面临挑战的时期对我们公司的支持，并使我们能够推进我们的制药和临床项目，以期在 2026 年获得批准并扩展，以支持有自杀倾向的抑郁症和创伤后应激障碍患者，” NRx Pharmaceuticals 及其子公司 HOPE Therapeutics 的董事长兼首席执行官 Jonathan Javitt 博士表示。</p>
<p><strong>关于 NRx Pharmaceuticals, Inc.</strong></p>
<p>NRx Pharmaceuticals, Inc.（www.nrxpharma.com）是一家临床阶段生物制药公司，开发基于其 NMDA 平台的治疗药物，针对中枢神经系统疾病，特别是自杀性抑郁症、慢性疼痛和创伤后应激障碍。公司正在开发 NRX-100（无防腐剂的静脉注射氯胺酮）和 NRX-101（口服 D-氨基酸/氟哌啶醇）。NRX-100 已获得针对抑郁症中自杀意念的快速通道认证，包括双相抑郁症。NRX-101 已获得针对自杀性双相抑郁症的突破性疗法认证。NRx 最近重新提交了简化新药申请（ANDA），并启动了 NRX-100 的新药申请，申请用于治疗抑郁症患者的自杀意念，包括双相抑郁症的国家优先券计划。</p>
<p><strong>关于前瞻性声明的通知</strong></p>
<p>此处包含的信息包括根据 1934 年证券交易法第 21E 条及 1933 年证券法第 27A 条的修订版的前瞻性声明。前瞻性声明通常包括预测性质的陈述，依赖于或涉及未来事件或条件，并包括诸如 “可能”、“将”、“应该”、“会”、“期望”、“计划”、“相信”、“打算”、“期待” 等类似表达。这些陈述涉及未来事件或公司的未来财务表现，并涉及已知和未知的风险、不确定性及其他因素，这些因素可能导致公司的实际结果与这些前瞻性声明所表达或暗示的任何未来结果、活动水平、表现或成就存在重大差异。公司已报告已实现的监管里程碑，但未预测任何未来监管决定的结果。您不应对前瞻性声明过于依赖，因为它们涉及已知和未知的风险、不确定性及其他因素，这些因素在某些情况下超出了公司的控制范围，并可能会对实际结果、活动水平、表现或成就产生重大影响。任何前瞻性声明反映了公司对未来事件的当前看法，并受这些及其他风险的影响，包括与公司运营、运营结果、增长战略及其他事项（包括流动性）相关的不确定性和假设。有关公司及可能影响前瞻性声明实现的风险因素的更详细信息已在公司最近的 10-K 表格年度报告及其他向证券交易委员会提交的文件中列出。投资者和证券持有人被敦促在 SEC 网站上免费阅读这些文件，网址为 <strong>http://www.sec.gov</strong>。除非适用法律要求，否则公司不承担公开更新或修订这些前瞻性声明的义务，或更新实际结果可能与这些前瞻性声明中预期的结果存在重大差异的原因，无论是由于新信息、未来事件还是其他原因。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>如需更多信息：</strong></td>
<td></td>
</tr>
<tr>
<td><strong><em>Matthew Duffy</em></strong> NRx 首席商务官<br/>(646) 335-5923<br/>mduffy@nrxpharma.com</td>
<td><strong><em>Brian Korb</em></strong><br/>管理合伙人，astr partners<br/>(917) 653-5122<br/>brian.korb@astrpartners.com</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05ESTJOU00zTXpJNE1EWXdJekl3T0RReE1qST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05ESTJOU00zTXpJNE1EWXdJekl3T0RReE1qST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTliNDExNWUtMTVmMy00YzM0LWJmNGEtYzRiMTk5ZTNiMTVkLTEwOTU2OTMtMjAyNS0xMi0xOC1lbg==/tiny/NRx-Pharmaceuticals-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTliNDExNWUtMTVmMy00YzM0LWJmNGEtYzRiMTk5ZTNiMTVkLTEwOTU2OTMtMjAyNS0xMi0xOC1lbg==/tiny/NRx-Pharmaceuticals-Inc.png"/></p>

NRXP

<p>NRX Pharmaceuticals 宣布通过股权转换消除其 540 万美元的债务，预计到 2025 年底实现无债务的资产负债表。这一战略举措为公司在 2026 年的加速增长奠定了基础，届时可能会有药物批准和临床扩展。公司对 Anson Funds 在生物技术股票面临挑战时期的支持表示感谢</p>

<ul>
<li>Remaining $5.4 million debt was repaid through strategic equity conversion in common stock with no additional warrants or adjustment provisions</li>
<li>Company anticipates that Dec 31 balance sheet will reflect no outstanding convertible debt</li>
<li>Debt-free balance sheet sets the stage for accelerated growth in 2026 with potential drug approvals and clinic expansions</li>
</ul>
<div class="lb-trans"><ul>
<li>剩余的 540 万美元债务通过战略性股权转换为普通股偿还，没有附加的认股权证或调整条款</li>
<li>公司预计截至 12 月 31 日的资产负债表将不再反映任何未偿还的可转换债务</li>
<li>无债务的资产负债表为 2026 年的加速增长奠定了基础，预计将有潜在的药物批准和诊所扩展</li>
</ul>
</div><p>WILMINGTON, Del., Dec. 18, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has repaid the remaining $5.4 million balance sheet debt to Anson Funds, LLC, through equity conversion of common stock. There were no warrants or other repricing mechanisms associated with this transaction. Anson originally lent $16.2 million USD to the Company to fund repayment of prior loans and corporate operating expenses. With this repayment, the Company anticipates ending the 2025 calendar year with a balance sheet free of all debt. NRx believes that this milestone properly positions the company’s capital structure for accelerated growth with anticipated drug approvals and clinic expansions in the coming year.</p>
<div class="lb-trans"><p>特拉华州威尔明顿，2025 年 12 月 18 日（GLOBE NEWSWIRE）-- NRx Pharmaceuticals, Inc.（纳斯达克：NRXP），一家临床阶段生物制药公司，今天宣布已通过普通股的股权转换向 Anson Funds, LLC 偿还了剩余的 540 万美元资产负债表债务。此交易没有附带认股权证或其他重新定价机制。Anson 最初向公司借款 1620 万美元，用于偿还之前的贷款和公司运营费用。通过此次偿还，公司预计在 2025 年日历年结束时将实现无债务的资产负债表。NRx 认为这一里程碑为公司的资本结构适当定位，以便在未来一年实现加速增长，预计将有药物批准和诊所扩展。</p>
</div><p>“We thank Anson Funds for supporting our Company during a challenging period for biotechnology equities and for enabling us to advance our pharmaceutical and clinical programs toward potential 2026 approval and expansion in support of patients with suicidal depression and PTSD,” said Dr. Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals and its subsidiary HOPE Therapeutics.</p>
<div class="lb-trans"><p>“我们感谢 Anson Funds 在生物技术股票面临挑战的时期对我们公司的支持，并使我们能够推进我们的制药和临床项目，以期在 2026 年获得批准并扩展，以支持有自杀倾向的抑郁症和创伤后应激障碍患者，” NRx Pharmaceuticals 及其子公司 HOPE Therapeutics 的董事长兼首席执行官 Jonathan Javitt 博士表示。</p>
</div><p><strong>About NRx Pharmaceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 NRx Pharmaceuticals, Inc.</strong></p>
</div><p>NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently re-filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.</p>
<div class="lb-trans"><p>NRx Pharmaceuticals, Inc.（www.nrxpharma.com）是一家临床阶段生物制药公司，开发基于其 NMDA 平台的治疗药物，针对中枢神经系统疾病，特别是自杀性抑郁症、慢性疼痛和创伤后应激障碍。公司正在开发 NRX-100（无防腐剂的静脉注射氯胺酮）和 NRX-101（口服 D-氨基酸/氟哌啶醇）。NRX-100 已获得针对抑郁症中自杀意念的快速通道认证，包括双相抑郁症。NRX-101 已获得针对自杀性双相抑郁症的突破性疗法认证。NRx 最近重新提交了简化新药申请（ANDA），并启动了 NRX-100 的新药申请，申请用于治疗抑郁症患者的自杀意念，包括双相抑郁症的国家优先券计划。</p>
</div><p><strong>Notice Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的通知</strong></p>
</div><p>The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#34;may,&#34; &#34;will,&#34; &#34;should,&#34; &#34;would,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;believe,&#34; &#34;intend,&#34; &#34;look forward,&#34; and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at <strong>http://www.sec.gov</strong>. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.</p>
<div class="lb-trans"><p>此处包含的信息包括根据 1934 年证券交易法第 21E 条及 1933 年证券法第 27A 条的修订版的前瞻性声明。前瞻性声明通常包括预测性质的陈述，依赖于或涉及未来事件或条件，并包括诸如 “可能”、“将”、“应该”、“会”、“期望”、“计划”、“相信”、“打算”、“期待” 等类似表达。这些陈述涉及未来事件或公司的未来财务表现，并涉及已知和未知的风险、不确定性及其他因素，这些因素可能导致公司的实际结果与这些前瞻性声明所表达或暗示的任何未来结果、活动水平、表现或成就存在重大差异。公司已报告已实现的监管里程碑，但未预测任何未来监管决定的结果。您不应对前瞻性声明过于依赖，因为它们涉及已知和未知的风险、不确定性及其他因素，这些因素在某些情况下超出了公司的控制范围，并可能会对实际结果、活动水平、表现或成就产生重大影响。任何前瞻性声明反映了公司对未来事件的当前看法，并受这些及其他风险的影响，包括与公司运营、运营结果、增长战略及其他事项（包括流动性）相关的不确定性和假设。有关公司及可能影响前瞻性声明实现的风险因素的更详细信息已在公司最近的 10-K 表格年度报告及其他向证券交易委员会提交的文件中列出。投资者和证券持有人被敦促在 SEC 网站上免费阅读这些文件，网址为 <strong>http://www.sec.gov</strong>。除非适用法律要求，否则公司不承担公开更新或修订这些前瞻性声明的义务，或更新实际结果可能与这些前瞻性声明中预期的结果存在重大差异的原因，无论是由于新信息、未来事件还是其他原因。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>For further information:</strong></td>
<td></td>
</tr>
<tr>
<td><strong><em>Matthew Duffy</em></strong> Chief Business Officer, NRx<br/>(646) 335-5923<br/>mduffy@nrxpharma.com</td>
<td><strong><em>Brian Korb</em></strong><br/>Managing Partner, astr partners<br/>(917) 653-5122<br/>brian.korb@astrpartners.com</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>如需更多信息：</strong></td>
<td></td>
</tr>
<tr>
<td><strong><em>Matthew Duffy</em></strong> NRx 首席商务官<br/>(646) 335-5923<br/>mduffy@nrxpharma.com</td>
<td><strong><em>Brian Korb</em></strong><br/>管理合伙人，astr partners<br/>(917) 653-5122<br/>brian.korb@astrpartners.com</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05ESTJOU00zTXpJNE1EWXdJekl3T0RReE1qST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwNDI2NSM3MzI4MDYwIzIwODQxMjI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTliNDExNWUtMTVmMy00YzM0LWJmNGEtYzRiMTk5ZTNiMTVkLTEwOTU2OTMtMjAyNS0xMi0xOC1lbg==/tiny/NRx-Pharmaceuticals-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/MTliNDExNWUtMTVmMy00YzM0LWJmNGEtYzRiMTk5ZTNiMTVkLTEwOTU2OTMtMjAyNS0xMi0xOC1lbg==/tiny/NRx-Pharmaceuticals-Inc.png"/></p>

NRX Pharmaceuticals（纳斯达克代码：NRXP）宣布通过股权转换消除所有资产负债表上的债务 | NRXP 股票新闻